Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature

Table 1 Characteristics of patients with HBV reactivation during or after DAA treatment for HCV published in literature

Patient	Ref.	Gender, age	HCV genotype	Previous IFN	DAA treatment	HBV profile	HIV status	Symptoms onset
1	[7]	M, 53	4d	Yes	SOF/LDV	Resolved HBV	+	At 6 weeks during DAA
2	[6]	M, 55	1a	Yes	SOF/SMV	Inactive HBV	-	At 8 weeks during DAA
3	[6]	M, 57	1a	Yes	SOF/SMV	Occult HBV	-	At 4 weeks during DAA
4	[10]	F, 59	1b	Yes	SOF/SMV/RBV	Resolved HBV	-	At 11 weeks during DAA
5	[9]	M, 69	1b	No	DCV/ASV	Inactive HBV	-	At 6 weeks during DAA
6	[8]	F, 83	1b	NA	DCV/ASV	NA (HBsAg neg)	-	At 20 weeks after DAA

Legend: M male, F female, IFN interferon, RBV ribavirin, SOF sofosbuvir, SMV simeprevir, DCV daclatasvir, ASV asunaprevir, HBV hepatitis B virus, HCV hepatitis C virus, DAA direct antiviral agents, NA not available, neg negative

ISSN: 1471-2334